Your browser doesn't support javascript.
loading
Characterization of a new component and impurities in josamycin by trap-free two-dimensional liquid chromatography coupled to ion trap time-of-flight mass spectrometry.
Liu, Guijun; Xu, Yu; Sang, Jing; Zhu, Bingqi; Wang, Jian.
Afiliação
  • Liu G; Zhejiang University of Technology, Hangzhou, 310014, China.
  • Xu Y; Zhejiang University of Technology, Hangzhou, 310014, China.
  • Sang J; Zhejiang Institute for Food and Drug Control, Hangzhou, 310052, China.
  • Zhu B; Zhejiang Institute for Food and Drug Control, Hangzhou, 310052, China.
  • Wang J; Zhejiang University of Technology, Hangzhou, 310014, China.
Rapid Commun Mass Spectrom ; 33(12): 1058-1066, 2019 Jun 30.
Article em En | MEDLINE | ID: mdl-30907019
ABSTRACT
RATIONALE The toxicities of the impurities of a drug will affect the clinical effects and cause potential health risk; therefore, it is essential to study profiles of the impurities. In this study, a new structural type of component and two acid degradation impurities in josamycin were discovered and characterized for the further improvement of official monographs in pharmacopoeias.

METHODS:

The component and acid degradation impurities in josamycin were separated and preliminary characterized by trap-free two-dimensional liquid chromatography coupled to high-resolution ion trap time-of-flight mass spectrometry (2D LC/IT-TOF MS) in both positive and negative electrospray ionization mode. The eluent of each peak from the first dimensional chromatographic system was trapped by a switching valve and subsequently transferred to the second dimensional chromatographic system, which was connected to the mass spectrometer. Full scan MS was firstly conducted to obtain the exact m/z values of the molecules. Then LC/MS/MS and LC/MS/MS/MS experiments were performed on the compounds of interest.

RESULTS:

A new structural type of component, which was named as josamycin A, and two acid degradation impuritiess, which were identified as impurity I and impurity II, were discovered in josamycin. Their structures and fragmentation pattern were deduced according to MSn data. Furthermore, josamycin A was synthesized and impurity I was separated by preparative HPLC. The structures of josamycin A and the impurities were confirmed by 1 H NMR and 13 C NMR data.

CONCLUSIONS:

Josamycin A was produced when the hydroxyl group on the macrolide of josamycin was oxidized into a carbonyl group. Impurity I and impurity II were produced by the loss of one molecule of acetyl mycaminose from josamycin and josamycin A, respectively. Compared with josamycin, the experimental results showed that josamycin A had a higher antibacterial activity with similar cytotoxicity, while impurity I had no antibacterial activity but a higher cytotoxicity. As a result, the control of impurity I is significant.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2019 Tipo de documento: Article